<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03716791</url>
  </required_header>
  <id_info>
    <org_study_id>16970-001</org_study_id>
    <nct_id>NCT03716791</nct_id>
  </id_info>
  <brief_title>The Effect of Methylsulfonylmethane (MSM) on Cardiometabolic Health</brief_title>
  <official_title>The Effect of Methylsulfonylmethane (MSM) on Cardiometabolic Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lindsey Miller</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity- related diseases are linked to elevated levels of inflammation, oxidative stress,
      and metabolic dysfunction. Methylsulfonylmethane (MSM) is a naturally occurring compound that
      demonstrates antioxidant and anti-inflammatory effects. Improvements in measures of metabolic
      health have been observed in mouse models of obesity and type 2 diabetes following MSM
      treatment. However, the effect of MSM on obesity-related risk factors for disease in humans
      has not been investigated. Therefore, the purpose of this investigation will be to determine
      whether MSM supplementation improves metabolic health, and markers of inflammation and
      oxidative status.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind placebo controlled randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline blood glucose at 4, 8, and 16 weeks</measure>
    <time_frame>0,4,8,16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline blood cholesterol at 4, 8, and 16 weeks</measure>
    <time_frame>0,4,8,16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline blood pressure at 4, 8, and 16 weeks</measure>
    <time_frame>0,4,8,16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline insulin at 4, 8, and 16 weeks</measure>
    <time_frame>0,4,8,16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline resting metabolic rate at 16 weeks</measure>
    <time_frame>0 and 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline percent body fat at 4, 8, and 16 weeks</measure>
    <time_frame>0,4,8,16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in waist circumference at 4, 8, and 16 weeks</measure>
    <time_frame>0,4,8,16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood markers of inflammation and oxidative stress at 4, 8, and 16 weeks</measure>
    <time_frame>0,4,8,16 weeks</time_frame>
    <description>Inflammatory markers will include c-reactive protein, interleukin-6, and Tumor necrosis factor-alpha. Oxidative stress will be determined by total antioxidant capacity assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pulmonary function tests</measure>
    <time_frame>0, 4, 8, 16 weeks</time_frame>
    <description>Pulmonary function tests include forced expiratory volume in 1 second to forced vital capacity ration and slow vital capacity measurement. Expired nitric oxide has also been included as a marker of pulmonary inflammation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>pill capsules containing white rice flour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylsulfonylmethane Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pill capsules containing MSM</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>methylsulfonylmethane</intervention_name>
    <description>3g per day</description>
    <arm_group_label>Methylsulfonylmethane Group</arm_group_label>
    <other_name>MSM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>white rice flour</description>
    <arm_group_label>Placebo Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  overweight or obese adults without any diagnosed disease or current medications other
             than birth control. Participants must agree to maintain diet and physical activity
             levels throughout study.

        Exclusion Criteria:

          -  normal weight adults, or overweight/obese adults that do not meet the criteria for
             metabolically unhealthy obesity. Individuals currently on medications, or with
             diagnosed disease. Pregnant or nursing women, or women planning to become pregnant
             within the study timeframe. Lack of access to reliable transportation to study site,
             lack of internet access, or non-english speaking.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsey E Miller, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lindsey E Miller, Ph.D</last_name>
    <phone>509-368-6733</phone>
    <phone_ext>5093686733</phone_ext>
    <email>lindsey.e.miller@wsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington State University</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malathi Jandhyala</last_name>
      <phone>509-335-3668</phone>
      <email>irb@wsu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 18, 2018</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Washington State University</investigator_affiliation>
    <investigator_full_name>Lindsey Miller</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimethyl sulfone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

